Arbutus Biopharma

Arbutus Biopharma Corp. is a biopharmaceutical company. It engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded in 2007 and is headquartered in Warminster, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Arbutus Biopharma advances promising drug candidates and secures financial stability

Arbutus Biopharma showcased progress in its drug development pipeline, particularly with positive Phase IIa trial results for AB-729 and the introduction of AB-343 as a promising oral coronavirus drug candidate. The company's financial stability and strategic focus on upcoming milestones position it well for future growth.

Arbutus Biopharma advances HBV and COVID-19 treatments with strong finances

Arbutus Biopharma is making significant progress in developing treatments for HBV and COVID-19, supported by a strong financial position.
While facing challenges such as FDA clinical holds and trial planning, the company is well-positioned to capitalize on upcoming opportunities.
Strategic focus on clinical advancements, financial stability, and future growth opportunities defines Arbutus Biopharma's outlook for 2023.

Arbutus Biopharma advances Hepatitis B cure development amid financial strength

Arbutus Biopharma is progressing well in its quest for a functional cure for chronic Hepatitis B, supported by a strong pipeline and financial stability.
The company faces challenges in navigating development hurdles and competition but has opportunities to lead in innovative therapies for HBV and COVID-19.
By focusing on key milestones, strategic trial designs, and effective resource management, Arbutus aims to drive growth and success in the biopharmaceutical sector.

Arbutus Biopharma focuses on HBV cure amid leadership transition

Arbutus Biopharma's strategic focus on developing a functional cure for chronic HBV and maintaining financial stability through 2026 positions the company for future growth.
While workforce reduction and legal challenges present hurdles, the company's pipeline progress and leadership transition signal resilience and adaptability.
Opportunities in pipeline expansion, partnerships, and clinical trial advancements underscore Arbutus Biopharma's potential for long-term success in the biopharmaceutical industry.

Arbutus Biopharma focuses on HBV cure, extends cash runway

Arbutus Biopharma's Q4 2023 earnings call highlighted a strategic focus on HBV and extending cash runway. Progress in clinical trials and ongoing litigation efforts against key players. Anticipating reduced cash burn in 2024 for financial sustainability.

Arbutus Biopharma reports strong financials and progresses HBV treatment pipeline

Arbutus Biopharma showcased a strong financial position and positive results in Phase 1a study of AB-836.
The company's focus on developing a functional cure for chronic HBV and advancing pipeline assets demonstrates commitment to innovation.
While facing questions on dosing strategies and trial designs, Arbutus sees opportunities in upcoming data releases and advancing clinical studies.

Arbutus Biopharma reports promising HBV trial results and financial strength

Arbutus Biopharma demonstrates positive trial results and financial stability, positioning the company well for future growth and innovation in HBV treatment
Challenges in trial design, data interpretation, and legal proceedings require careful navigation to capitalize on opportunities for advancement
Opportunities lie in further data reporting, biomarker exploration, and potential partnerships to drive progress towards a functional cure for chronic hepatitis B

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the Hepatitis B virus, SARS-CoV-2, and other coronaviruses. The company was founded on October 6, 2005 and is headquartered in Warminster, PA.

Arbutus Biopharma Corporation (NASDAQ:ABUS ) Q3 2022 Earnings Conference Call January 1, 2022 8:45 AM ET Company Participants Lisa Caperelli - Vice President of Investor Relations Bill Collier - President and Chief Executive Officer David Hastings - Chief Financial Officer Gaston Picchio - Chief Development Officer Mike Sofia - Chief Scientific Officer Conference Call Participants Dennis Ding - Jefferies Roy Buchanan - JMP Keay Nakae - Chardan Operator Good day. And thank you for standing by, and welcome to Arbutus Biopharma Corporation's 2022 Third Quarter Financial Results and Corporate Update Conference Call.

Arbutus Biopharma Corporation (ABUS) Q3 2022 Earnings Call Transcript

Financially strong with a projected cash runway into the  second quarter of 2024

Arbutus Reports Third Quarter 2022 Financial Results and Provides Corporate Update

HBsAg and HBV DNA remain at low levels with no evidence of clinical relapse up to 44 weeks after discontinuing AB-729 and NA therapy

Arbutus Presents AB-729 Clinical Data and AB-101 Preclinical Data at AASLD - The Liver Meeting®

Conference Call and Webcast to discuss the new data being presented at AASLD scheduled for 8:45 AM ET, Friday, November 4, 2022

Arbutus Announces Three Poster Presentations with Clinical Data from AB-729 and Preclinical Data from AB-101 at AASLD - The Liver Meeting® 2022

WARMINSTER, Pa., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled its third quarter 2022 financial results and corporate update for Wednesday, November 9, 2022. The schedule for the press release and conference call/webcast are as follows:

Arbutus to Report Third Quarter 2022 Financial Results and Provide Corporate Update

WARMINSTER, Pa., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that Gaston Picchio, PhD, Chief Development Officer, will be leaving the Company for personal reasons. Dr. Picchio will continue to serve as CDO until his departure on December 31, 2022. The Company has initiated a search for Dr. Picchio's replacement.

Gaston Picchio, PhD, Chief Development Officer, to Depart Arbutus at Year End

WARMINSTER, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the Company will participate in a fireside chat at Chardan's 6th Annual Genetic Medicines Conference taking place in New York on Tuesday, October 4, 2022 at 2:30 pm ET.

Arbutus to Present at Chardan's 6th Annual Genetic Medicines Conference

WARMINSTER, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the Company will participate in the following upcoming investor conferences taking place in New York:

Arbutus to Participate in September Investor Conferences

WARMINSTER, Pa., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,427,823, which provides composition of matter patent protection for Arbutus' AB-729 RNAi therapeutic product. The patent is expected to provide Arbutus with exclusivity for AB-729 out to at least April 2038.

Arbutus Biopharma Announces Issuance of a New Key U.S. Patent Related to AB-729

Arbutus Biopharma Corporation (NASDAQ:ABUS ) Q2 2022 Earnings Conference Call August 4, 2022 8:45 AM ET Company Participants Lisa Caperelli - Vice President of Investor Relations Bill Collier - President & Chief Executive Officer David Hastings - Chief Financial Officer Gaston Picchio - Chief Development Officer Mike Sofia - Chief Scientific Officer Conference Call Participants Roy Buchanan - JMP Securities Dennis Ding - Jefferies Brian Skorney - Baird Keay Nakae - Chardan Thomas Yip - H.C. Wainwright Operator Good morning.

Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q2 2022 Results - Earnings Call Transcript

Key milestones across our chronic hepatitis B virus (cHBV) and  pan-coronavirus programs remain on track

Arbutus Reports Second Quarter 2022 Financial Results and Provides Corporate Update

WARMINSTER, Pa., July 21, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled its second quarter 2022 financial results and corporate update for Thursday, August 4, 2022. The schedule for the press release and conference call/webcast are as follows:

Arbutus to Report Second Quarter 2022 Financial Results and Provide Corporate Update

Triple combination clinical trial evaluating AB-729, an RNAi therapeutic, vebicorvir, Assembly Biosciences' core inhibitor, and nucleos(t)ide analog continues with data expected in 2H 2022

Arbutus Biopharma Provides Update on the Phase 2A Combination Trial with AB-729 and a Capsid Inhibitor

Arbutus (ABUS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Arbutus (ABUS) Rating Upgrade to Buy

Two triple-combination studies using AB-729 for treatment of patients with Hepatitis B are expected in the 2nd half of 2022. A PD-L1 drug is being advanced in the pipeline to eventually add to a triple combination regimen with AB-729; In addition, potential to advance very same drug for oncology use.

Arbutus: 2 Key Catalysts To Look Forward To After EASL Data Release

JMP Securities reiterates its Market Outperform rating but reduces the price target to $9 from $10 on Arbutus Biopharma Corp (NASDAQ: ABUS) after data presentation at the European Association for the Study of the Liver International Liver Congress. The analysts said that.

This Analyst Says Arbutus' EASL Presentations Outline Path For A Functional Cure For Chronic Hepatitis B

AB-729, our RNAi therapeutic, provided robust and comparable HBsAg declines in both HBeAg+ and HBeAg- patients

Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress™ 2022 and Provides AB-836 Clinical Update

ContraFect

Eiger BioPharmaceuticals

IVERIC bio Inc

Eli Lilly

Pfizer

SQZ Biotechnologies

Three weeks ago, I suggested that the severe correction in biopharmaceutical stocks had ended. I expect the bottoming process to be choppy with a bias to the upside. The antecedent cause of the decline was the "Class of 2021 IPOs", which featured many companies with preclinical compounds, yet valuations exceeded $1 billion.

Biopharmaceutical Stocks: The Bottoming Process Is Playing Out

Conference Call & Webcast to discuss new data being presented at EASL ILC 2022 scheduled for June 27, 2022 at 8:00 am ET

Arbutus to Present Seven Scientific Posters at EASL International Liver Congress™ 2022

WARMINSTER, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the Company will participate in the following upcoming investor conferences taking place in New York:

Arbutus to Participate in June Investor Conferences

WARMINSTER, Pa., May 26, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that its abstract on a preclinical oncology study for one of Arbutus' oral PD-L1 inhibitor compounds designed to reawaken the immune system, has been selected for publication at the American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3-7, 2022.

Arbutus Announces Abstract Selected for Publication at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

WARMINSTER, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that William Collier, Arbutus' President and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference on Tuesday, May 24, 2022, at 11:30 am ET in Miami, FL.

Arbutus to Present at H.C. Wainwright Global Investment Conference

Arbutus Biopharma Corp, Inc. (NASDAQ:ABUS ) Q1 2022 Earnings Conference Call May 5, 2022 8:45 AM ET Company Participants Lisa Caperelli - VP, IR William Collier - President, CEO & Director Michael Sofia - Chief Scientific Officer David Hastings - CFO & CAO Gaston Picchio - Chief Development Officer Conference Call Participants Douglas Buchanan - JMP Securities Yuchen Ding - Jefferies Thomas Yip - H.C. Wainwright & Co. Luke Herrmann - Robert W.

Arbutus Biopharma Corp (ABUS) CEO William Collier on Q1 2022 Results - Earnings Call Transcript

Arbutus Reports First Quarter 2022 Financial Results and Provides Corporate Update

WARMINSTER, Pa., April 21, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled its first quarter 2022 financial results and corporate update for Thursday, May 5, 2022. The schedule for the press release and conference call/webcast are as follows:

News for Arbutus Biopharma Stock (ABUS)